An OBGYN voices frustration — “silently cursing behind my mask” – with the patients who “recite a litany of scientifically illiterate reasons for not taking” the COVID-19 vaccine despite its 99%+ effectiveness in keeping them alive. Do you share this doctor’s sentiments?

Research shows that the “old” 2015 recommendation would only identify about half of Americans with prediabetes and undiagnosed type 2 diabetes. Based on this data, the US Preventive Services Task Force has lowered the recommended screening age from 40 to 35 years in asymptomatic, nonpregnant adults who are overweight or obese.

This Q&A with Dana Farber’s Dr. Rinath Jeselsohn centers on fulvestrant (Faslodex, AZ) and its current role in the management of breast cancer, as well as outlining the emerging selective estrogen receptor degraders (SERDs), their clinical trial data, potential for use, and whether the options will become the “backbone” of endocrine therapy in HER2-negative metastatic breast cancer.

An oncologist pens an essay about his 10-year-old son who died in March 2021 from diffuse midline glioma, providing a glimpse into his own extreme truths about the burden he carries in treating cancer patients.

Publication: JAMA OncologyMethod: Retrospective study of 160 adults with hematologic malignant disease who were vaccinated with 1 of 3 COVID-19 vaccines (February through April 2021).Results: Patients receiving B-cell-depleting immunotherapy may not gain adequate protection from vaccination and may still develop a potentially fatal infection.

Can you differentiate between bradykinin-mediated angioedema and the more common histamine-mediated angioedema? How significant is a delayed diagnosis? Do you favor on-demand or preventative therapy? What is the recommended therapy? Access to specialist care and effective treatment in the past 10 years has improved the quality of life and reduced the mortality rate in patients with hereditary angioedema. This wide-ranging report from the British Journal of Hospital Medicine covers emerging treatments and outlines where we’ve been, where we are, and where we’re going in hereditary angioedema (HAE) care.